Pharmaceutical company Galenika has acquired a 100% stake in Slovenia-based Sanofarm, reinforcing its market position in Slovenia and Croatia and advancing its strategic expansion within the European Union.
The acquisition also grants Galenika exclusive distribution rights for products from Italian manufacturers Pharmalife Research and ESI in Slovenia, as well as the Pharmalife brand in Croatia—broadening Galenika’s portfolio in natural products and dietary supplements.
“Since becoming part of Brazil’s NC Group, we have consistently strengthened our international presence and aligned our portfolio with modern consumer needs,” said Ricardo Vian Marques, CEO of Galenika. “The acquisition of Sanofarm is an important step in our internationalisation, deepening our partnership with Pharmalife Research and expanding our offer with ESI’s well-regarded phytotherapeutic and dietary products.”
Sanofarm is an established distributor of dietary supplements and phytotherapeutic products with a strong footprint in Slovenia and Croatia. By integrating Sanofarm’s portfolio with its own, Galenika aims to unlock operational synergies, improve product availability, and enhance consumer choice across both markets.
The transaction further solidifies Galenika’s presence in the EU, increases the visibility of established brands, and supports a more diverse, high-quality offering for consumers in the Adria region. Galenika said it will continue Sanofarm’s good business practices toward employees and partners, while strengthening corporate governance and pursuing long-term, sustainable growth.
